Overview

Generic Name(s):
bcg vaccine
NCI Definition [1]:
A vaccine containing bacillus Calmette-Guerin (BCG), an attenuated strain of Mycobacterium bovis, with non-specific immunoadjuvant and immunotherapeutic activities. Although the mechanism of its anti-tumor activity is unclear, immunization with BCG vaccine likely activates a Th1 cytokine response that includes the induction of interferon. Vaccination with BCG vaccine may be immunoprotective against infection with Mycobacterium tuberculosis.

Bcg vaccine has been investigated in 2 clinical trials, of which 2 are open and 0 are closed. Of the trials investigating bcg vaccine, 1 is phase 2 (1 open) and 1 is phase 3 (1 open).

Bladder urothelial carcinoma and renal pelvis and ureter urothelial carcinoma are the most common diseases being investigated in bcg vaccine clinical trials [2].

Drug Details

Synonyms [2]:
pacis, attenuated bacillus calmette guerin, bacillus calmette guerin vaccine, vaccine, bcg, bacillus calmette-guerin vaccine, bcg tice, bacillus calmette-guerin, bacillus calmette guerin, cultivo bcg, bcg vaccine, imovax bcg, attenuated bacillus calmette guerin (substance), bcg tice, pastimmun, bacille calmette-guerin live, bacillus calmette guerin vaccine, tice bcg, bcg vaccine [chemical/ingredient], vaccine, calmette's, bacillus calmette-guerin vaccine, bacillus calmette-guérin vaccine, immucyst, bcg, bcg vaccine, monovax, oncotice, calmette's vaccine, calmette vaccine, bacillius calmette-guerin vaccine, live intravesical bcg, tice bcg, calmettes vaccine, theracys, mycobacterium bovis (strain bcg), attenuated bacillus calmette guerin (product), oncotice, bcg (pasteur), bacillus calmette-guerin vaccine, calmette guerin bacillus vaccine
NCIT ID [1]:
C298
SNOMED ID [1]:
F-6209B

References

1. National Cancer Institute. NCI Thesaurus Version 18.11d. https://ncit.nci.nih.gov/ncitbrowser/. [2018-07-30] [2018-08-02].

2. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.